|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We aimed at establishing a real-time PCR protocol for the detection of the venous thromboembolism associated mutations factor V Leiden (F5 c.1691G>A; p.R506Q) and prothrombin (F2) c.20210G>A from whole blood, without DNA extraction.
|
30439355 |
2019 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Factor V G1691A (FV-Leiden) and prothrombin (PRT) G20210A single nucleotide polymorphisms (SNPs) are major inherited risk factors of venous thromboembolism.
|
16261289 |
2005 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Insofar as the inherited prothrombotic single nucleotide polymorphisms (SNPs) factor V G1691A (FV-Leiden), prothrombin (PRT) G20210A, and methylenetetrahydrofolate reductase (MTHFR), C677T are inherited risk factors of venous thromboembolism (VTE), the aim of this study was to determine the prevalence of single and combined SNPs in 198 patients with documented deep venous thrombosis (DVT), and 697 control subjects, and to estimate the associated risks.
|
16082606 |
2005 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Statistically significant associations with VTE were identified for factor V G1691A (OR 9.45; 95% CI 6.72-13.30, p < 0.0001), factor V A4070G (OR 1.24; 95% CI 1.02-1.52, p = 0.03), prothrombin G20210A, (OR 3.17; 95% CI 2.19-3.46, p < 0.00001), prothrombin G11991A, (OR 1.17; 95% CI 1.07-1.27, p = 0.0007), PAI-1 4G/5G, (OR 1.62; 95% CI 1.22-2.16, p = 0.0008), alpha-fibrinogen Thr312Ala (OR 1.37; 95% CI 1.14-1.64, p = 0.0008), all in Caucasian populations.
|
19652888 |
2009 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Venous thromboembolism at a young age in a brother and sister with coinheritance of homozygous 20210A/A prothrombin mutation and heterozygous 1691G/A factor V Leiden mutation.
|
10456622 |
1999 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The coexistence of FV G1691A and elevated Lp(a) was significantly more prevalent among patients with VTE than in the control group (7% versus 0.8%; P <.001, OR 9.8, 95% CI, 2.4-40.7).
|
11071628 |
2000 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Coagulation factor II G20210A and coagulation factor V (Leiden) G1691A single nucleotide polymorphisms (SNPs) are major inherited risk factors of venous thromboembolism.
|
22744422 |
2012 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The protein C (PC), protein S, antithrombin activities, homocysteine levels, and factor V Leiden (FVL) G1691A and prothrombin G20210A mutations were evaluated in 191 patients with VTE and 191 controls.
|
17895505 |
2008 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T mutations are considered risk factors for venous thromboembolism.
|
15886665 |
2005 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, coagulant factor V gene G1691A mutation and protein S deficiency constitute important genetic risk factors in patients with VTE in Eastern Algeria.
|
26304686 |
2017 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Factor V Leiden (Factor V G1691A), prothrombin gene mutation G20210A, and homozygous C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene are known to predispose venous thromboembolism (VTE).
|
19520679 |
2010 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation.
|
10365737 |
1999 |
|
rs552953108
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Because both factor V R506Q</span> and the HR2 haplotype are very frequent, the effect of their coinheritance on the risk of venous thromboembolism might represent a clinically relevant issue, and screening for HR2 in carriers of factor V R506Q should be considered.
|
10556190 |
1999 |
|
rs552953108
|
|
|
0.060 |
GeneticVariation |
BEFREE |
We developed a genome-wide polygenic risk score for venous thromboembolism that identifies 5% of the population at an equivalent incident venous thromboembolism risk to carriers of the established factor V Leiden p.R506Q and prothrombin G20210A mutations.
|
31676865 |
2019 |
|
rs552953108
|
|
|
0.060 |
GeneticVariation |
BEFREE |
We aimed at establishing a real-time PCR protocol for the detection of the venous thromboembolism associated mutations factor V Leiden (F5 c.1691G>A; p.R506Q) and prothrombin (F2) c.20210G>A from whole blood, without DNA extraction.
|
30439355 |
2019 |
|
rs552953108
|
|
|
0.060 |
GeneticVariation |
BEFREE |
The determination of the factor II: G20210A variant in index patients carrying a factor V: R506Q mutation and, if present, in family members may help to identify individuals who are at high risk for VTE.
|
11737249 |
2001 |
|
rs552953108
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Factor V leiden G1691A/R506Q (FVL), prothrombin G20210A (FII) and methylenetetrahydrofolate reductase (MTHFR) C677T are related genetic risk factors for venous thromboembolism.
|
22528331 |
2012 |
|
rs552953108
|
|
|
0.060 |
GeneticVariation |
BEFREE |
In non-oral contraceptive users the risk of venous thromboembolism was significantly increased in carriers of R506Q but not in those with the G20210A mutation.
|
12069454 |
2002 |
|
rs1183194405
|
|
|
0.020 |
GeneticVariation |
BEFREE |
To investigate the possible role of factor XIII Val34Leu in the pathogenesis of venous thromboembolism (VTE) and potential interactions with factor V Leiden (FV:Q506) and prothrombin G --> A 20210, we studied 221 patients with a history of VTE and 254 healthy controls.
|
9920839 |
1999 |
|
rs1183194405
|
|
|
0.020 |
GeneticVariation |
BEFREE |
There was no interaction between the fibrinogen Aalpha-Thr312Ala and FXIII Val34Leu polymorphisms for the risk of VTE.
|
17568659 |
2007 |
|
rs387907201
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Two different prothrombin variants, p.Arg596Leu and p.Arg596Gln, conferring antithrombin resistance to patients with venous thromboembolism have been recently reported.
|
27013614 |
2016 |
|
rs387907201
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Prothrombin Arg596Gln mutation is a risk factor for Chinese patients with VTE due to its moderately decreased clotting activity but strong resistance to antithrombin inhibition.
|
29331940 |
2018 |
|
rs1183827513
|
|
|
0.010 |
GeneticVariation |
BEFREE |
New Prothrombin Mutation (Arg596Trp, Prothrombin Padua 2) Associated With Venous Thromboembolism.
|
27013614 |
2016 |
|
rs776445885
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The relationship between VTE and the VKORCI 1173C > T polymorphism was consistent with a recessive model.
|
17883698 |
2007 |
|
rs780225764
|
|
|
0.010 |
GeneticVariation |
BEFREE |
FV A1090G, FV A1299G mutations, and PAI-1 gene polymorphisms may not be a risk factor for VTE in Turkish population.
|
21078611 |
2012 |